Waldman, A. D., Fritz, J. M. & Lenardo, M. J. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat. Rev. Immunol. 20, 651–668 (2020).
Goebeler, M. E. & Bargou, R. C. T cell-engaging therapies—BiTEs and beyond. Nat. Rev. Clin. Oncol. 17, 418–434 (2020).
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A. & June, C. H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725–733 (2011).
Sharma, P. & Allison, J. P. The future of immune checkpoint therapy. Science 348, 56–61 (2015).
Bhoj, V. G. et al. Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy. Blood 128, 360–370 (2016).
Leach, D. R., Krummel, M. F. & Allison, J. P. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271, 1734–1736 (1996).
Vesely, M. D., Kershaw, M. H., Schreiber, R. D. & Smyth, M. J. Natural innate and adaptive immunity to cancer. Annu. Rev. Immunol. 29, 235–271 (2011).
Trabolsi, A., Arumov, A. & Schatz, J. H. T cell-activating bispecific antibodies in cancer therapy. J. Immunol. 203, 585–592 (2019).
Wu, L. et al. Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation. Nat. Cancer 1, 86–98 (2020).
Steinmetz, A. et al. CODV-Ig, a universal bispecific tetravalent and multifunctional immunoglobulin format for medical applications. MAbs 8, 867–878 (2016).
Berchuck, A. et al. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res. 50, 4087–4091 (1990).
Burstein, H. J. The distinctive nature of HER2-positive breast cancers. N. Engl. J. Med. 353, 1652–1654 (2005).
Gravalos, C. & Jimeno, A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann. Oncol. 19, 1523–1529 (2008).
Kim, E. K., Kim, K. A., Lee, C. Y. & Shim, H. S. The frequency and clinical impact of HER2 alterations in lung adenocarcinoma. PLoS ONE 12, e0171280 (2017).
Pollock, N. I. & Grandis, J. R. HER2 as a therapeutic target in head and neck squamous cell carcinoma. Clin. Cancer Res. 21, 526–533 (2015).
Santin, A. D. et al. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma. Cancer 104, 1391–1397 (2005).
Siena, S. et al. Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer. Ann. Oncol. 29, 1108–1119 (2018).
Slamon, D. J. et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177–182 (1987).
Yoon, H. H. et al. Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas. Clin. Cancer Res. 18, 546–554 (2012).
Hicks, D. G. & Kulkarni, S. HER2+ breast cancer: review of biologic relevance and optimal use of diagnostic tools. Am. J. Clin. Pathol. 129, 263–273 (2008).
Pohlmann, P. R., Mayer, I. A. & Mernaugh, R. Resistance to trastuzumab in breast cancer. Clin. Cancer Res. 15, 7479–7491 (2009).
Shak, S. Overview of the trastuzumab (herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group. Semin. Oncol. 26, 71–77 (1999).
Wang, J. & Xu, B. Targeted therapeutic options and future perspectives for HER2-positive breast cancer. Signal Transduct. Target Ther. 4, 34 (2019).
Laux, I. et al. Response differences between human CD4(+) and CD8(+) T-cells during CD28 costimulation: implications for immune cell-based therapies and studies related to the expansion of double-positive T-cells during aging. Clin. Immunol. 96, 187–197 (2000).
Brudno, J. N. & Kochenderfer, J. N. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood 127, 3321–3330 (2016).
Kroschinsky, F. et al. New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management. Crit. Care 21, 89 (2017).
Saber, H., Del Valle, P., Ricks, T. K. & Leighton, J. K. An FDA oncology analysis of CD3 bispecific constructs and first-in-human dose selection. Regul. Toxicol. Pharmacol. 90, 144–152 (2017).
Baselga, J. et al. Phase II study of weekly intravenous trastuzumab (herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Semin. Oncol. 26, 78–83 (1999).
Zuch de Zafra, C. L. et al. Targeting multiple myeloma with AMG 424, a novel anti-CD38/CD3 bispecific T-cell-recruiting antibody optimized for cytotoxicity and cytokine release. Clin. Cancer Res. 25, 3921–3933 (2019).
Harbeck, N. et al. HER2 dimerization inhibitor pertuzumab—mode of action and clinical data in breast cancer. Breast Care (Basel) 8, 49–55 (2013).
Niculescu-Duvaz, I. Trastuzumab emtansine, an antibody-drug conjugate for the treatment of HER2+ metastatic breast cancer. Curr. Opin. Mol. Ther. 12, 350–360 (2010).
Bang, Y. J. et al. First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors. Ann. Oncol. 28, 855–861 (2017).
Jones, K. L. & Buzdar, A. U. Evolving novel anti-HER2 strategies. Lancet Oncol. 10, 1179–1187 (2009).
Mignot, F. et al. Concurrent administration of anti-HER2 therapy and radiotherapy: systematic review. Radiother. Oncol. 124, 190–199 (2017).
Vu, T. & Claret, F. X. Trastuzumab: updated mechanisms of action and resistance in breast cancer. Front. Oncol. 2, 62 (2012).
Buie, L. W., Pecoraro, J. J., Horvat, T. Z. & Daley, R. J. Blinatumomab: a first-in-class bispecific T-cell engager for precursor B-cell acute lymphoblastic leukemia. Ann. Pharmacother. 49, 1057–1067 (2015).
Tran, B. et al. 609O Results from a phase I study of AMG 160, a half-life extended (HLE), PSMA-targeted, bispecific T-cell engager (BiTE®) immune therapy for metastatic castration-resistant prostate cancer (mCRPC). Ann. Oncol. 31, s507 (2020).
Deegen, P. et al. The PSMA-targeting half-life extended BiTE therapy AMG 160 has potent antitumor activity in preclinical models of metastatic castration-resistant prostate cancer. Clin. Cancer Res. 27, 2928–2937 (2021).
Raghu, G. et al. SAR156597 in idiopathic pulmonary fibrosis: a phase 2 placebo-controlled study (DRI11772). Eur. Respir. J. 52, 1801130 (2018).
Merchant, A. M. et al. An efficient route to human bispecific IgG. Nat. Biotechnol. 16, 677–681 (1998).
Xu, L. et al. Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques. Science 358, 85–90 (2017).
Alegre, M. L. et al. A non-activating “humanized” anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo. Transplantation 57, 1537–1543 (1994).
Smith, K. B. & Ellis, S. A. Standardisation of a procedure for quantifying surface antigens by indirect immunofluorescence. J. Immunol. Methods 228, 29–36 (1999).
https://www.nature.com/articles/s41586-022-04439-0